Intrinsiqq
Semnur Pharmaceuticals, Inc. logo

Semnur Pharmaceuticals, Inc.

SMNR

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$33M
EPS-$0.06
P/E-2.50
P/FCF-3.07
EV/EBITDA-1.88
FCF Yield–
Div. Yield–
Net Debt/FCF-0.2x
Semnur Pharmaceuticals, Inc. intrinsic value
52-Week Range
$0.15$0.45

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$19M

▼ -3320.4% YoY

Op. Margin

–

ROIC

-548.57%

▼ -5483.3pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$11M

▼ -21.2% YoY

Op. Cash Flow (TTM)

-$11M

▼ -20.0% YoY

Net Debt

$2M

Cash & Equiv.

$54K

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with SMNR

CompareIntrinsic value
CTNMContineum Therapeutics, Inc.
$8.68-3.98%10
KALVKalVista Pharmaceuticals Inc.
No recent price25
AQSTAquestive Therapeutics Inc.
$3.46-6.61%10
XOMAXOMA Corporation
€0.04-3.86%64
OCULOcular Therapeutix Inc.
$5.57-4.95%10
CARMCarisma Therapeutics Inc.
$0.00+0.00%60
SPROSpero Therapeutics Inc.
$0.74-10.17%25
GOSSGossamer Bio Inc.
$10.72-4.54%10

Semnur Pharmaceuticals (SMNR) in three numbers

Quality score
0/100
Best check: revenue growth, 0.0%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-2.50
Negative: a loss over the last twelve months. Price to free cash flow -3.07.
Financials

Questions about Semnur Pharmaceuticals

Is Semnur Pharmaceuticals a high-quality business?

Semnur Pharmaceuticals scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is revenue growth at 0.0%. The Quality tab shows every check against its target.

Does Semnur Pharmaceuticals (SMNR) pay a dividend?

No. Semnur Pharmaceuticals (SMNR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 133.0% buyback yield. The Dividends tab shows its cash returns.

Source: 10-Q filed 4 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in SMNR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing SMNR

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.